FDA 483 - BPI Labs LLC - April 30, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of BPI Labs LLC in Largo, FL, a sterile drug manufacturer and 503B outsourcing facility, revealed multiple deficiencies in equipment qualification, supplier management, and risk analysis. The firm failed to install and qualify labeling equipment, adequately evaluate suppliers for critical components, and conduct comprehensive risk analyses for its combination products. These observations indicate significant issues in the firm's quality system and compliance with regulatory requirements.
ID · 69fc33ad-b67c-4880-a657-dd7fb2d6c393